TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00526292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer cell therapy
Description: The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Day -5 fludarabine 25mg/m2 CIV for 5 days
Study: NCT03799796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring with Online Peer Support
Description: Hispanic Adults who are Spanish-Speaking with type 2 diabetes who are not using insulin will be asked to use flash glucose monitoring and to sign up for an moderated online peer support group where they can ask questions and share progress.
Study: NCT04123522

Intervention type: PROCEDURE
Intervention: anterior approach
Description: anterior approach

Intervention type: PROCEDURE
Intervention: posterior appraoch
Description: posteiror appraoch
Study: NCT02314936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litesse powder containing 12 g polydextrose
Description: 12 g polydextrose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litesse powder containing 8 g polydextrose
Description: 8 g polydextrose, 4 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litesse powder containing 4 g polydextrose
Description: 4 g polydextrose, 8 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 g Maltodextrin
Study: NCT04139655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: Oral colchicine given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
Study: NCT03418155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of TongBi Capsule
Description: TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment of TongBi placebo
Description: TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
Study: NCT03166982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic approach
Study: NCT04154748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation 90W power

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Plasma Coagulation 90W power

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Plasma Coagulation 60W power

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 120 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 120 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 40 mg
Study: NCT00175019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, tablets, orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 120 mg, tablets, orally, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
Study: NCT00968370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day-care clinic
Description: Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.

Intervention type: OTHER
Group type: OTHER
Intervention: Hospital Management
Description: Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
Study: NCT05701683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri Probiotic
Description: Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy
Study: NCT03396133

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Snap
Description: screen, transmission, and analysis ECG automated
Study: NCT04085770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 1 MCG Oral Capsule
Description: 2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay
Study: NCT04749602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 40 mg of the nivolumab will be used intrapleurally (once).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 40 mg of the nivolumab will be used intrapleurally (once).
Study: NCT01471522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiac catheterization
Description: Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery bypass graft surgery
Description: Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: diet, physical activity, smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: diet, physical activity, smoking cessation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Study: NCT01408966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DarkChocolate
Description: Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: WhiteChocolate
Description: White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt \& Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
Study: NCT01617954

Intervention type: DEVICE
Intervention: MammaPrint
Description: All subjects
Study: NCT00712673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
Study: NCT01336829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR/telaprevir
Description: Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278/telaprevir
Description: Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir/ETR
Description: Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir/TMC278
Description: Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
Study: NCT00712673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study: NCT02586259

Intervention type: DRUG
Intervention: budesonide MMX®
Study: NCT04544176

Intervention type: OTHER
Intervention: Observational
Description: There will be no interventions in this study, it is purely observational using data already collected.

Intervention type: OTHER
Intervention: Observational
Description: There will be no interventions in this study, it is purely observational using data already collected.
Study: NCT00101608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Description: solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
Study: NCT00712673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study: NCT05839496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercises
Description: Patients learned the activation of deep cervical flexor and extensor muscles. Then, during the activity of deep cervical muscles, superficial cervical muscles and upper extremity muscles were also strengthened. Thus, it was aimed to strengthen all neck muscles and upper extremity muscles in different positions synchronously and to increase their endurance.
Study: NCT02293304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-etch approach
Description: The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
Study: NCT03913858

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Obesity Surgery with Low-Flow Anesthesia
Description: Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Obesity Surgery with High-Flow Anesthesia
Description: Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.
Study: NCT03174353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Prefilled Syringe
Description: All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
Study: NCT01069484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum pelvic floor muscle training
Description: Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
Study: NCT01506271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam 250 mg
Description: Relebactam 250 mg IV every 6 hours for a minimum of 96 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam 125 mg
Description: Relebactam 125 mg IV every 6 hours for a minimum of 96 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imipenem/cilastatin
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to relebactam
Description: Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
Study: NCT03597815

Intervention type: DRUG
Intervention: Aflibercept 40 MG/ML [Eylea]
Description: Intravitreal injection, form of anti-VEGF therapy

Intervention type: DRUG
Intervention: Aflibercept 40 MG/ML [Eylea]
Description: Intravitreal injection, form of anti-VEGF therapy

Intervention type: DIAGNOSTIC_TEST
Intervention: OSA diagnostic test - overnight sleep study
Description: Overnight with specialist care in hospital - heart, lung and brain activity monitored.

Intervention type: DIAGNOSTIC_TEST
Intervention: OSA diagnostic test - overnight sleep study
Description: Overnight with specialist care in hospital - heart, lung and brain activity monitored.

Intervention type: DIAGNOSTIC_TEST
Intervention: OSA diagnostic test - overnight sleep study
Description: Overnight with specialist care in hospital - heart, lung and brain activity monitored.

Intervention type: DIAGNOSTIC_TEST
Intervention: OSA diagnostic test - overnight sleep study
Description: Overnight with specialist care in hospital - heart, lung and brain activity monitored.

Intervention type: DEVICE
Intervention: CPAP therapy for OSA positive patients
Description: positive airway pressure ventilator, applies mild air pressure in a continuous basis to keep the airways continuously open in patients who are able to breath spontaneously on their own.

Intervention type: DEVICE
Intervention: CPAP therapy for OSA positive patients
Description: positive airway pressure ventilator, applies mild air pressure in a continuous basis to keep the airways continuously open in patients who are able to breath spontaneously on their own.
Study: NCT04338282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: 240mg/d, every 3 weeks, for up to one year or until disease progression, whichever comes first
Study: NCT02293304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse approach
Description: After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
Study: NCT04353973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Test Intervention
Description: Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Test Intervention
Description: Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
Study: NCT01813916

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: proteomic analysis
Study: NCT02464436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hRPC
Description: Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
Study: NCT00528957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: Tenofovir DF (oral powder or tablet): 300-mg tablets for participants \> 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to \> 37 kg may be switched from the oral powder to the tenofovir DF tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Zidovudine as prescribed by the investigator prior to study entry (pediatric participants \< 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m\^2 every 8 hours; pediatric participants \> 12 years of age: 300 mg twice daily).
Study: NCT00804726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Akreos MI Five-O
Description: Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
Study: NCT04072926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioRoot
Description: Influence of biomaterial BioRoot on periapical healing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioRoot
Description: Influence of biomaterial BioRoot on periapical healing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioRoot
Description: Influence of biomaterial BioRoot on periapical healing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioRoot
Description: Influence of biomaterial BioRoot on periapical healing
Study: NCT01244685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deltex CardioQ Probe
Description: Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
Study: NCT03111238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REX-001
Description: REX-001 is administered through an intra-arterial catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered through an intra-arterial catheter.
Study: NCT02446184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal Cystoscopy
Description: Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal vesicoamniotic shunt
Description: Fetal vesicoamniotic shunt will be performed under ultrasound guidance
Study: NCT04033562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine patch
Description: Lidocaine patch will be applied at time of Cesarean delivery for post-operative pain control.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr
Description: Infusion pump will be placed at time of Cesarean delivery for post-operative pain control.
Study: NCT01402440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study: NCT01207635

Intervention type: PROCEDURE
Intervention: Ductal Lavage Fluid Collection
Description: Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
Study: NCT02955056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forsteo
Description: 20 micrograms/80 microlitres solution for injection in pre-filled pen
Study: NCT00866177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given orally